Suppr超能文献

拉丁美洲非肌层浸润性膀胱癌管理中的挑战与机遇:来自医疗服务提供者和患者倡导组织的见解

Challenges and opportunities in NMIBC management across Latin America: insights from healthcare providers and a patient advocacy group.

作者信息

McCully Mark, Lipkis Julia, Heller Aryel, Huñis Adrian

机构信息

PharmaValue Partners, 603 Mattison Avenue, Suite 319, Asbury Park, NJ 07712, USA.

A. Hunis & Associates, Oncology Consultants, Hollywood, FL 33019, USA.

出版信息

Ecancermedicalscience. 2024 Jun 7;18:1711. doi: 10.3332/ecancer.2024.1711. eCollection 2024.

Abstract

Non-muscle invasive bladder cancer (NMIBC) is characterised by high rates of recurrence and progression, requiring substantial healthcare resources. In Latin America, the incidence of NMIBC is set to increase due to an aging population and lifestyle changes. To better understand the current challenges for NMIBC treaters and patients, a mixed-methods approach was leveraged combining secondary research with qualitative interviews from healthcare providers in Brazil, Colombia, Mexico and Argentina. Our analysis found that significant challenges persist across the region, particularly due to Calmette-Guérin shortages, inconsistent adherence to clinical guidelines and significant socioeconomic disparities for patients accessing healthcare services. Addressing these challenges requires improved patient advocacy, strategic use of clinical trials and better resource distribution to enhance NMIBC management across Latin America.

摘要

非肌层浸润性膀胱癌(NMIBC)的特点是复发率和进展率高,需要大量医疗资源。在拉丁美洲,由于人口老龄化和生活方式的改变,NMIBC的发病率呈上升趋势。为了更好地了解NMIBC治疗者和患者目前面临的挑战,我们采用了混合方法,将二手研究与来自巴西、哥伦比亚、墨西哥和阿根廷的医疗服务提供者的定性访谈相结合。我们的分析发现,该地区仍然存在重大挑战,特别是由于卡介苗短缺、对临床指南的依从性不一致以及患者获得医疗服务方面存在巨大的社会经济差异。应对这些挑战需要加强患者宣传、战略性地利用临床试验以及更好地分配资源,以加强拉丁美洲对NMIBC的管理。

相似文献

1
Challenges and opportunities in NMIBC management across Latin America: insights from healthcare providers and a patient advocacy group.
Ecancermedicalscience. 2024 Jun 7;18:1711. doi: 10.3332/ecancer.2024.1711. eCollection 2024.
4
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
9
Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2024 Aug;7(4):760-769. doi: 10.1016/j.euo.2023.10.003. Epub 2023 Oct 24.

本文引用的文献

2
Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.
Front Oncol. 2023 Jun 2;13:1170124. doi: 10.3389/fonc.2023.1170124. eCollection 2023.
4
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice.
Nat Rev Clin Oncol. 2023 May;20(5):287-304. doi: 10.1038/s41571-023-00744-3. Epub 2023 Mar 13.
5
An updated profile of the cancer burden, patterns and trends in Latin America and the Caribbean.
Lancet Reg Health Am. 2022 Sep;13:None. doi: 10.1016/j.lana.2022.100294.
9
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
10
Increasing costs from bladder cancer in the Brazilian Health System: the role of establishing public health policies.
Int Braz J Urol. 2021 Mar-Apr;47(2):443-447. doi: 10.1590/S1677-5538.IBJU.2020.0658.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验